D-Wave Quantum Inc. Files 8-K for Regulation FD Disclosure

TL;DR

DWAVE filed an 8-K for a Reg FD disclosure - check for new info.

AI Summary

On October 1, 2024, D-Wave Quantum Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure, indicating that the company has made material information available to the public. No specific financial transactions or material events beyond this disclosure are detailed in the provided excerpt.

Why It Matters

This filing signals that D-Wave Quantum Inc. has publicly disseminated important information, which is crucial for investors to stay informed about the company's developments.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure and does not contain information about significant financial risks or operational changes.

Key Players & Entities

• D-Wave Quantum Inc. (company) — Registrant
• October 1, 2024 (date) — Date of Report
• Regulation FD Disclosure (disclosure) — Item Information

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share QBTS New York Stock Exchange
• $11.50 — of common stock at an exercise price of $11.50 QBTS.WT New York Stock Exchange Indic

Filing Documents

• qbts-20241001.htm (8-K) — 32KB
• exhibit991-jtpressreleasef.htm (EX-99.1) — 9KB
• 0001907982-24-000112.txt ( ) — 207KB
• qbts-20241001.xsd (EX-101.SCH) — 2KB
• qbts-20241001_def.xml (EX-101.DEF) — 15KB
• qbts-20241001_lab.xml (EX-101.LAB) — 27KB
• qbts-20241001_pre.xml (EX-101.PRE) — 16KB
• qbts-20241001_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 1, 2024, D-Wave Quantum Inc. ("D-Wave") and the pharmaceutical division of Japan Tobacco Inc. ("JT") announced plans to collaborate on a joint proof-of-concept project that will leverage quantum computing technology and artificial intelligence ("AI") in the drug discovery process. Supported by D-Wave's team of professional services experts, the AI team in JT's pharmaceutical division will utilize D-Wave's annealing quantum computing solutions as accelerators in the speed and quality of training JT's novel AI-driven analysis systems, aiming to extend the applicable range of such AI systems in the drug discovery field. The goal of the project is to pioneer a new process for discovering 'first-in-class' pharmaceutical small compounds. A copy of the press release is attached as Exhibit 99.1. The information in this Item 7.01 to this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits . (d) Exhibits Exhibit No. Description 99.1 Press release, dated October 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 1, 2024 D-Wave Quantum Inc. By: /s/ Alan Baratz Name: Alan Baratz Title: President & Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR